Keywords
Prediction
Pre-eclampsia
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Describe which biomarkers are related to severe preeclampsia or not and what are the main conclusions about them. Methods: This is a study with a qualitative approach, through an integrative literature review. The databases used were: PubMed, Literatura Latino-americana e do Caribe em Ciências da Saúde (LILACS) e Cochrane Library (CL). To search for articles on the platforms, the descriptors “biochemical markers”, “prediction” and “pre-eclampsia” were used. Results: After applying inclusion and exclusion criteria, 23 articles were selected. Among the results, placental growth factor (PlFG) and soluble fms-like tyrosine kinase-1 (sFlt-1) were highlighted, which are indicated as having a promising use in the screening and prediction of PE cases. Final considerations: PlGF and sFlt-1, and their correlation (PlGF/sFtl-1), are believed to be more reliably associated with risk stratification of PE as well as predicting delivery.
References
BLANKLEY RT, et al. A label-free selected reaction monitoring workflow identifies a subset of pregnancy specific glycoproteins as potential predictive markers of early-onset pre-eclampsia. Mol Cell Proteomics, 2013; 12(11): 3148-59.
BOUCOIRAN I, et al. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. Am J Perinatol., 2013; 30(7): 607-12.
BRASIL. Secretária do Estado da Saúde, Governo de Santa Catarina. A pré-eclâmpsia afeta até 7% das brasileiras. 2019. Disponível em: https://www.saude.sc.gov.br/index.php/noticias-geral/todas-as-noticias/1641-noticias-2019/10661-a-pre-eclampsia-afeta-ate-7-das-brasileiras#:~:text=Quase%2076%20mil%20m%C3%A3es%20e,e%207%25%20das%20gr%C3%A1vidas%20brasileiras. Acessado em: 13 de jan de 2022.
CERDEIRA AS, et al. Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE. Hypertension, 2019; 74(4): 983-990.
DE VIVO A, et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand., 2008; 87(8): 837-42.
DELIĆ R, et al. Statistical regression model of standard and new laboratory markers and its usefulness in prediction of preeclampsia. J Matern Fetal Neonatal Med., 2014; 27(4): 388-92.
DUNDAR O, et al. Longitudinal study of platelet size changes in gestation and predictive power of elevated MPV in development of preeclampsia. Prenat Diagn., 2008; 28: 1052–6.
FARINA A, et al. Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia. Prenat Diagn., 2011; 31(12): 1147-52.
GAMMILL HS, et al. Does C-reactive protein predict recurrent preeclampsia? Hypertens Pregnancy, 2010; 29(4): 399-409.
HAYES-RYAN D, et al. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland). BMJ, 2021; 374: 1857.
KARUMANCHI SA, GRANGER JP. Preeclampsia and Pregnancy-Related Hypertensive Disorders. Hypertension, 2016; 67(2): 238-42.
KASHANIAN M, et al. Evaluation of the diagnostic value of the first-trimester maternal serum high-sensitivity C-reactive protein level for prediction of pre-eclampsia. J Obstet Gynaecol Res., 2013; 39(12): 1549-54.
KUMARI M, et al. Circulating NT-proBNP but not soluble corin levels were associated with preeclampsia in pregnancy-associated hypertension. Clin Biochem., 2019; 67: 12-15.
MEIRI H, et al. Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin. J Perinat Med., 2014; 42(5): 591-601.
MOORE SIMAS TA, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol., 2007; 197(3): 244-8.
MULLER F, et al. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. Am J Obstet Gynecol., 1996; 175: 37-40.
MURTONIEMI K, et al. Prediction of pre-eclampsia and its subtypes in high-risk cohort: hyperglycosylated human chorionic gonadotropin in multivariate models. BMC Pregnancy Childbirth., 2018; 18(1): 279.
MYATT L, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?. BJOG, 2013; 120(10): 1183-91.
MYERS JE, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG, 2013; 120(10): 1215-23.
OZAT M, et al. Serum concentrations of CA-125 in normal and preeclamptic pregnancies. Arch Gynecol Obstet., 2011; 284(3): 607-12.
PERRY H, et al. Angiogenic Marker Prognostic Models in Pregnant Women With Hypertension. Hypertension, 2020; 75(3): 755-761.
PHIPPS EA, et al. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275-289.
POON LC, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet., 2019; 145: 1-33.
RANA S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation, 2012; 125(7): 911-9.
SCHOOFS K, et al. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med., 2014; 42(1): 61-8.
SHU C, et al. Protein profiling of preeclampsia placental tissues. PLoS One, 2014; 9(11): 112.
SIBAI BM, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol., 2008; 199(3): 268.
STAMILIO DM, et al. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol., 2000; 182(3): 589-94.
YANG SW, et al. Significance of the platelet distribution width as a severity marker for the development of preeclampsia. Eur J Obstet Gynecol Reprod Biol., 2014; 175: 107-11.
YOUSSEF A, et al. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. Prenat Diagn., 2011; 31(12): 1141-6.
ZEISLER H, et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med., 2016; 374: 13–22.